Bone Health and Osteoporosis

被引：210

作者：

Lupsa, Beatrice C. ^{[1
]}

Insogna, Karl ^{[1
]}

机构：

[1] Yale Univ, Sch Med, Dept Internal Med, Yale Bone Ctr, New Haven, CT 06510 USA

来源：

ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA | 2015年 / 44卷 / 03期

关键词：

Osteoporosis; Menopause; Fracture; Bone loss; Bone mineral density; DXA; Calcium; Vitamin D; FRACTURE INTERVENTION TRIAL; RANDOMIZED CONTROLLED-TRIAL; POSTMENOPAUSAL WOMEN; DIETARY-PROTEIN; ESTABLISHED OSTEOPOROSIS; BIOCHEMICAL MARKERS; VERTEBRAL FRACTURES; ZOLEDRONIC ACID; MINERAL DENSITY; CLINICAL-TRIAL;

D O I：

10.1016/j.ecl.2015.05.002

中图分类号：

R5 [内科学];

学科分类号：

100201 [内科学];

摘要：

Osteoporosis is characterized by low bone mass and microarchitectural deterioration of bone tissue leading to decreased bone strength and an increased risk of low-energy fractures. Central dual-energy X-ray absorptiometry measurements are the gold standard for determining bone mineral density. Bone loss is an inevitable consequence of the decrease in estrogen levels during and following menopause, but additional risk factors for bone loss can also contribute to osteoporosis in older women. A well-balanced diet, exercise, and smoking cessation are key to maintaining bone health as women age. Pharmacologic agents should be recommended in patients at high risk for fracture.

引用

页码：517 / +

页数：16

共 35 条

[1]

[Anonymous], 2013, CLIN GUID PREV TREAT

[2]

Bartl R., 2009, Osteoporosis: Diagnosis, prevention, therapy

[3]

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis [J].

Black, Dennis M. ;

Delmas, Pierre D. ;

Eastell, Richard ;

Reid, Ian R. ;

Boonen, Steven ;

Cauley, Jane A. ;

Cosman, Felicia ;

Lakatos, Peter ;

Leung, Ping Chung ;

Man, Zulema ;

Mautalen, Carlos ;

Mesenbrink, Peter ;

Hu, Huilin ;

Caminis, John ;

Tong, Karen ;

Rosario-Jansen, Theresa ;

Krasnow, Joel ;

Hue, Trisha F. ;

Sellmeyer, Deborah ;

Eriksen, Erik Fink ;

Cummings, Steven R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (18) :1809-1822

[4]

Continuing Bisphosphonate Treatment for Osteoporosis - For Whom and for How Long? [J].

Black, Dennis M. ;

Bauer, Douglas C. ;

Schwartz, Ann V. ;

Cummings, Steven R. ;

Rosen, Clifford J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (22) :2051-2053

[5]

The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT) [J].

Black, Dennis M. ;

Reid, Ian R. ;

Boonen, Steven ;

Bucci-Rechtweg, Christina ;

Cauley, Jane A. ;

Cosman, Felicia ;

Cummings, Steven R. ;

Hue, Trisha F. ;

Lippuner, Kurt ;

Lakatos, Peter ;

Leung, Ping Chung ;

Man, Zulema ;

Martinez, Ruvie Lou Maria ;

Tan, Monique ;

Ruzycky, Mary Ellen ;

Su, Guoqin ;

Eastell, Richard .

JOURNAL OF BONE AND MINERAL RESEARCH, 2012, 27 (02) :243-254

[6]

Effects of continuing or stopping alendronate after 5 years of treatment - The Fracture Intervention Trial long-term extension (FLEX): A randomized trial [J].

Black, Dennis M. ;

Schwartz, Ann V. ;

Ensrud, Kristine E. ;

Cauley, Jane A. ;

Levis, Silvina ;

Quandt, Sara A. ;

Satterfield, Suzanne ;

Wallace, Robert B. ;

Bauer, Douglas C. ;

Palermo, Lisa ;

Wehren, Lois E. ;

Lombardi, Antonio ;

Santora, Arthur C. ;

Cummings, Steven R. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 296 (24) :2927-2938

[7]

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures [J].

Black, DM ;

Cummings, SR ;

Karpf, DB ;

Cauley, JA ;

Thompson, DE ;

Nevitt, MC ;

Bauer, DC ;

Genant, HK ;

Haskell, WL ;

Marcus, R ;

Ott, SM ;

Torner, JC ;

Quandt, SA ;

Reiss, TF ;

Ensrud, KE .

LANCET, 1996, 348 (9041) :1535-1541

[8]

A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study [J].

Chesnut, CH ;

Silverman, S ;

Andriano, K ;

Genant, H ;

Gimona, A ;

Harris, S ;

Kiel, D ;

LeBoff, M ;

Maricic, M ;

Miller, P ;

Moniz, C ;

Peacock, M ;

Richardson, P ;

Watts, N ;

Baylink, D .

AMERICAN JOURNAL OF MEDICINE, 2000, 109 (04) :267-276

[9]

Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis [J].

Chesnut, CH ;

Skag, A ;

Christiansen, C ;

Recker, R ;

Stakkestad, JA ;

Hoiseth, A ;

Felsenberg, D ;

Huss, H ;

Gilbride, J ;

Schimmer, RC ;

Delmas, PD .

JOURNAL OF BONE AND MINERAL RESEARCH, 2004, 19 (08) :1241-1249

[10]

BONE TURNOVER IN POSTMENOPAUSAL OSTEOPOROSIS - EFFECT OF CALCITONIN TREATMENT [J].

CIVITELLI, R ;

GONNELLI, S ;

ZACCHEI, F ;

BIGAZZI, S ;

VATTIMO, A ;

AVIOLI, LV ;

GENNARI, C .

JOURNAL OF CLINICAL INVESTIGATION, 1988, 82 (04) :1268-1274

← 1 2 3 4 →